BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Sanochemia Diagnostics International And N-Dia, Inc. Announce Licensing Of AmniSure


10/19/2005 5:11:05 PM

VIENNA, NEUSS, Germany and NEW YORK, April 28 /PRNewswire/ -- Sanochemia Diagnostics International, an associated company of Sanochemia Pharmazeutika AG, Vienna, has secured distribution rights of AmniSure(TM) for Germany, Austria, Switzerland and UK. This PROM rapid test (PROM= premature rupture of fetal membranes) is used for pregnant women presenting for assessment of membranes rupture. It is manufactured by N-Dia Inc, New York.

AmniSure(TM) is a point-of-care-test (POCT) which detects premature ruptures of the amniotic membrane. This indication is one of the most frequent reasons for premature birth and besides other complications during pregnancy counts responsible for an increased mortality risk for mother and baby. This clinical condition may be in question in up to 35% of all pregnancies. Therefore the exact and premature proof of a membrane rupture helps to reduce in this case complications during pregnancy. AmniSure(TM) has been approved by the FDA as the only PROM test worldwide to depict such clinical conditions.

With AmniSure(TM) Sanochemia Diagnostics takes another important step to consolidate its franchise in the in-vitro diagnostic markets of "Women' s health". It has been launched in Germany and will be launched in Austria, Switzerland and the UK shortly. "Due to our strong presence on important European markets, we hope to take a significant share of the market soon. That means a great progress in our strategic goals", said Dr. Bruno Rosen, Managing Director of Sanochemia Diagnostics Deutschland GmbH.

"N-Dia is committed to the field of diagnostics of pregnancy complications. We are happy to develop core European markets with Sanochemia Diagnostics", says Dr. Michael Friedman, CEO of N-Dia, Inc.

Sanochemia Pharmazeutika AG is an Austrian research-based pharmaceutical corporation specialised in the research and development of therapeutics for the indication of the central nervous system. In addition to the development and production of synthetic agents the company dedicates to the sale of contrast media and diagnostics via the associated company Sanochemia Diagnostics International, based in Neuss near Dusseldorf, Germany.

N-Dia, Inc. is based in New York, USA. The compay's main focus is on developing and marketing products for rapid diagnostics. Most of N-Dia's products utilize monoclonal antibodies to detect proteins associated with particular diseases. The company has developed a platform technology that minimizes false positive and false negative results in diagnostic testing and markets its products through a worldwide network of distributors.

SANOCHEMIA Pharmazeutika AG

CONTACT: Media contact: M Hoch, Email: m.hoch@sanochemia.at, Phone:+43-1-31914-56/35, Fax: +43-1-31914-56/44


Read at BioSpace.com

Related News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->